Mehmet Kemal Samur

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.

Sewastianik T, Straubhaar JR, Zhao JJ, Samur MK, Adler K, Tanton HE, Shanmugam V, Nadeem O, Dennis PS, Pillai V, Wang J, Jiang M, Lin J, Huang Y, Brooks D, Bouxsein M, Dorfman DM, Pinkus GS, Robbiani DF, Ghobrial IM, Budnik B, Jarolim P, Munshi NC, Anderson KC, Carrasco RD.

Blood. 2021 Apr 08. 137(14):1905-1919. PMID: 33751108

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.

Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC.

Nat Commun. 2021 02 08. 12(1):868. PMID: 33558511

Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13.

Song Y, Du T, Ray A, Chauhan K, Samur M, Munshi N, Chauhan D, Anderson KC.

Blood Cancer J. 2021 Jan 13. 11(1):13. PMID: 33441535

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.

Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, García Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H.

Blood. 2020 12 24. 136(26):3033-3040. PMID: 33367546

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N.

Blood Adv. 2020 12 08. 4(23):5988-5999. PMID: 33284948

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.

Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai YT, Adamia S, Ando K, Hideshima T, Anderson KC.

Blood. 2020 11 12. 136(20):2334-2345. PMID: 32844992

Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset.

Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong KL, Hungria VTM, Engelhardt M, Gay F, Garcia-Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum CA, Kumar SK, Stadtmauer E, Einsele H, Beksac M, Weisel KC, Anderson KC, Mateos MV, Moreau P, San Miguel J, Munshi NC, Avet-Loiseau H.

Blood. 2020 Nov 06. PMID: 33156904

YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.

Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R, Bianchi G, Tai YT, Anderson KC, Qiu L, Munshi NC.

Blood. 2020 07 23. 136(4):468-479. PMID: 32187357

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.

Samur MK, Aktas Samur A, Fulciniti M, Szalat R, Han T, Shammas M, Richardson P, Magrangeas F, Minvielle S, Corre J, Moreau P, Thakurta A, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC.

J Clin Oncol. 2020 09 20. 38(27):3107-3118. PMID: 32687451

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

Holstein SA, Howard A, Avigan D, Bhutani M, Cohen AD, Costa LJ, Dhodapkar MV, Gay F, Gormley N, Green DJ, Hillengass J, Korde N, Li Z, Mailankody S, Neri P, Parekh S, Pasquini MC, Puig N, Roodman GD, Samur MK, Shah N, Shah UA, Shi Q, Spencer A, Suman VJ, Usmani SZ, McCarthy PL.

Biol Blood Marrow Transplant. 2020 10. 26(10):e247-e255. PMID: 32589921